Ignite Creation Date:
2025-12-25 @ 3:24 AM
Ignite Modification Date:
2026-05-30 @ 2:01 AM
Study NCT ID:
NCT05272605
Status:
COMPLETED
Last Update Posted:
2023-05-15
First Post:
2022-03-03
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety and Immune Response of Adjuvanted SARS-CoV-2 (COVID-19) Beta Variant RBD Recombinant Protein (DoCo-Pro-RBD-1 + MF59®) and mRNA (MIPSCo-mRNA-RBD-1) Vaccines in Healthy Adults
Sponsor:
University of Melbourne
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
UoM-SARS-CoV-2-01
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |